Our Pricing

Your Mounjaro Questions Answered

Published on: June 03, 2026

Searching for mounjaro questions answered UK by qualified pharmacy professionals? At Cured Pharmacy, our UK-registered clinical team addresses the most common queries about tirzepatide treatment, from mechanism of action to eligibility criteria, helping you make an informed decision about this MHRA-licensed weight loss medication.

How Does Mounjaro Work for Weight Loss?

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing enhanced metabolic effects that reduce appetite, slow gastric emptying, and improve insulin sensitivity.

In the landmark SURMOUNT-1 trial, participants receiving the highest maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. This dual-receptor mechanism distinguishes Mounjaro from earlier GLP-1-only treatments, with clinical data suggesting superior weight loss outcomes across multiple dosing strengths [2].

The medication works by mimicking natural hormones your body produces after eating, signalling fullness to your brain and reducing food intake without requiring conscious calorie restriction. Most patients report diminished hunger and smaller portion sizes within the first few weeks of treatment, though individual responses vary based on baseline metabolism and adherence to lifestyle modifications.

What Are the Common Mounjaro Side Effects?

The most frequently reported side effects of Mounjaro are gastrointestinal in nature, occurring in approximately 20-30% of patients during dose escalation [1]. These include nausea, diarrhoea, constipation, vomiting, and abdominal discomfort, typically peaking within 72 hours of injection and diminishing as your body adjusts to each new dose strength.

Most gastrointestinal symptoms are mild to moderate and transient, resolving within 4-7 days without intervention. Our clinical team recommends starting with smaller meals, avoiding high-fat foods during the first week after dose increases, and maintaining adequate hydration to minimise discomfort. Severe or persistent vomiting requiring medical attention occurs in fewer than 2% of patients [2].

Serious but rare adverse effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly when combined with other diabetes medications). Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Mounjaro. Your UK prescriber will assess your complete medical history during consultation to ensure suitability and discuss monitoring requirements.

Managing Side Effects Effectively

If you experience persistent nausea beyond the first week, try taking your injection on an empty stomach before bed, allowing you to sleep through initial symptoms. Ginger tea, small frequent meals, and avoiding strong food odours can provide additional relief. Contact your prescriber if symptoms interfere with daily activities or prevent adequate nutrition and hydration.

Am I Eligible for Mounjaro Treatment?

Mounjaro is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [3]. Your eligibility is determined during a clinical assessment by a UK-registered prescriber who reviews your medical history, current medications, and contraindications.

Patients with certain conditions cannot safely use Mounjaro, including those with a history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy requiring active treatment. Pregnant or breastfeeding individuals should not use tirzepatide, and women of childbearing potential should use reliable contraception during treatment [4].

At Cured Pharmacy, our free online consultation takes under three minutes and connects you with UK prescribers who assess your suitability based on current MHRA guidelines. If Mounjaro is not appropriate for your circumstances, alternative weight management treatments may be recommended based on your individual clinical profile.

BMI Requirements and Exceptions

While standard eligibility requires a BMI of 30 or above, patients with a BMI of 27-29.9 may qualify if they have documented weight-related health conditions that would benefit from significant weight reduction. Your prescriber will evaluate laboratory results, blood pressure readings, and medical records to determine whether you meet the lower BMI threshold with comorbidities.

Mounjaro vs Wegovy: Key Differences Explained

Both Mounjaro and Wegovy are injectable medications licensed by the MHRA for chronic weight management, but they differ in their pharmacological mechanisms and clinical outcomes. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist, whilst Wegovy contains semaglutide, a GLP-1 receptor agonist only [1][2].

Head-to-head comparisons suggest tirzepatide produces greater average weight loss than semaglutide at equivalent treatment durations. In the SURMOUNT-1 trial, patients on the 15mg tirzepatide dose lost an average of 22.5% body weight over 72 weeks [1], compared to 14.9% weight loss with 2.4mg semaglutide in the STEP-1 trial over 68 weeks [2]. However, individual responses vary, and some patients may achieve better outcomes or tolerate one medication more comfortably than the other.

Dosing schedules are similar for both treatments, with once-weekly subcutaneous injections and gradual dose escalation to minimise side effects. Mounjaro is available at Cured Pharmacy from £124.99, whilst Wegovy starts from a lower entry price point. Your UK prescriber will consider your medical history, previous treatment responses, budget, and personal preferences when recommending the most suitable option.

How Quickly Will I See Results with Mounjaro?

Most patients begin noticing appetite suppression and reduced food cravings within 3-7 days of their first injection, though measurable weight loss typically becomes evident after 4-6 weeks of consistent treatment [1]. The medication requires gradual dose escalation over 16-20 weeks to reach maintenance strength, with progressive weight reduction throughout this titration period.

Clinical trial data shows the most significant weight loss occurs between weeks 20 and 72, as patients reach and maintain therapeutic doses [1]. Average monthly weight loss ranges from 2-4% of total body weight during the escalation phase, accelerating once maintenance doses are achieved. Patients who combine Mounjaro with dietary modifications and increased physical activity typically experience faster and more sustained results.

It is important to maintain realistic expectations and understand that weight loss is not linear. Some weeks may show minimal change whilst others demonstrate more dramatic reductions. Our superintendent pharmacist Tarun Kumar advises patients to focus on non-scale victories such as improved energy levels, better-fitting clothes, and enhanced metabolic markers rather than fixating solely on weekly weigh-ins.

Maximising Your Treatment Outcomes

To optimise results, maintain a food diary during the first month to identify portion size changes and hunger patterns. Aim for 150 minutes of moderate-intensity activity weekly, prioritise protein intake to preserve lean muscle mass during weight loss, and attend follow-up consultations to adjust dosing as needed. Consistency with injection timing and lifestyle modifications significantly influences final outcomes.

How to Access Mounjaro Through Cured Pharmacy

Accessing Mounjaro through Cured Pharmacy begins with our free online consultation, which takes under three minutes to complete from any device. You'll answer questions about your medical history, current medications, weight loss goals, and any previous weight management treatments. Our UK-registered prescribers review every submission individually, typically providing clinical decisions within 24 hours.

If approved, your prescription is dispensed by our GPhC-registered pharmacy (registration number 9012511) and dispatched in 100% discreet packaging with tracked delivery. We supply only genuine UK-licensed Mounjaro KwikPens sourced through regulated pharmaceutical wholesalers, ensuring product authenticity and proper cold-chain storage throughout the supply process.

Ongoing support includes follow-up consultations to monitor progress, adjust dosing schedules, and address any concerns about side effects or treatment response. Our clinical team remains available via phone (+44 116 4646009) during business hours for urgent queries. Repeat prescriptions can be requested through your online account, with automatic reminders sent before your current supply runs out to ensure uninterrupted treatment.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg solution for injection in pre-filled pen. GOV.UK. https://www.gov.uk/government/publications/mounjaro-tirzepatide [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment and lifestyle modifications.